fool.com · 27 jun

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.

fool.com · 27 jun

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally

Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction represented 11.60% of Advisors Llc Orbimed's total indirect holdings, reducing indirect ownership from 7,415,225 to 6,555,102 shares.

prnewswire.com · 15 jun

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.

gurufocus.com · 11 jun

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire

prnewswire.com · 11 jun

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,733,333 shares of Enliven's common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.

prnewswire.com · 11 jun

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock.

seekingalpha.com · 11 jun

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

prnewswire.com · 11 jun

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIs Favorable safety and tolerability profile with 161 patients enrolled and a median treatment duration of 35 weeks Alignment with the FDA on 80 mg QD as the recommended Phase 3 dose and on the 2L+ patient population for the ENABLE-2 pivotal trial, which is expected to initiate in the second half of this year BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today presented updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML).